|
Products |
| Products |
|
Diseases |  |
News |  |
| «12...5960616263646566676869...39323933» |
- | Keytruda (pembrolizumab) / Merck (MSD), Erbitux (cetuximab) / Eli Lilly, EMD Serono
Journal: Pembrolizumab plus cetuximab with neoadjuvant chemotherapy for head and neck squamous cell carcinoma. (Pubmed Central) - Aug 14, 2024
Pembrolizumab plus cetuximab with chemotherapy for patients with HNSCC is a feasible and safe clinical protocol fulfilling organ preservation and life quality improvement. Pre-treatment peripheral immune estimators could help to screen patients who may respond to the neoadjuvant immunochemotherapy.
- | tomivosertib (eFT508) / eFFECTOR Therap
Journal: Selective and effective suppression of pancreatic cancer through MNK inhibition. (Pubmed Central) - Aug 14, 2024
The MNK-eIF4E-?-catenin axis plays a critical role in pancreatic cancer progression and chemoresistance, distinguishing pancreatic cancer cells from normal cells. Targeting MNK kinases with inhibitors like eFT508 presents a promising therapeutic strategy for pancreatic cancer, with potential for selective efficacy and reduced toxicity.
- || Talvey (talquetamab-tgvs) / J&J
Enrollment closed: MonumenTAL-2: A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma (clinicaltrials.gov) - Aug 14, 2024
P1, N=167, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Targeting MNK kinases with inhibitors like eFT508 presents a promising therapeutic strategy for pancreatic cancer, with potential for selective efficacy and reduced toxicity. Recruiting --> Active, not recruiting
- || vidutolimod (CMP-001) / Regeneron
Trial completion, Combination therapy, Monotherapy, Metastases: CMP-001-011: CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma (clinicaltrials.gov) - Aug 14, 2024
P2/3, N=20, Completed, Sponsor: Regeneron Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | Campath (alemtuzumab) / Sanofi, polyTregs / National Institute of Allergy and Infectious Diseases
Trial completion date, Trial primary completion date: PolyTreg Immunotherapy in Islet Transplantation (clinicaltrials.gov) - Aug 14, 2024
P1, N=18, Active, not recruiting, Sponsor: University of Alberta
Active, not recruiting --> Completed Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Aug 2022 --> Aug 2024
- || Tecvayli (teclistamab-cqyv) / Genmab, J&J, Talvey (talquetamab-tgvs) / J&J
Enrollment closed, Enrollment change, Combination therapy, Checkpoint inhibition: TRIMM-3: A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 14, 2024
P1, N=74, Active, not recruiting, Sponsor: Janssen Research & Development, LLC
Trial completion date: May 2024 --> Oct 2024 | Trial primary completion date: Aug 2022 --> Aug 2024 Recruiting --> Active, not recruiting | N=152 --> 74
- |||| Jaypirca (pirtobrutinib) / Eli Lilly, Tecartus (brexucabtagene autoleucel) / Gilead
New P2 trial: Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL (clinicaltrials.gov) - Aug 13, 2024
P2, N=60, Not yet recruiting, Sponsor: H. Lee Moffitt Cancer Center and Research Institute
- | Lunsumio (mosunetuzumab-axgb) / Roche
Enrollment open, Trial initiation date: Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma (clinicaltrials.gov) - Aug 13, 2024
P3, N=600, Recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting | N=152 --> 74 Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> Apr 2025
- | Talvey (talquetamab-tgvs) / J&J
Trial completion date: A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 13, 2024
P1, N=15, Active, not recruiting, Sponsor: Janssen Pharmaceutical K.K.
Not yet recruiting --> Recruiting | Initiation date: Aug 2024 --> Apr 2025 Trial completion date: Aug 2024 --> Aug 2025
- | defactinib (VS-6063) / Verastem, Opdivo (nivolumab) / BMS, avutometinib (VS-6766) / Verastem
Enrollment open, Combination therapy, IO biomarker, Metastases: Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer (clinicaltrials.gov) - Aug 13, 2024
P2, N=50, Recruiting, Sponsor: Emory University
Trial completion date: Aug 2024 --> Aug 2025 Not yet recruiting --> Recruiting
- | Opdualag (nivolumab/relatlimab-rmbw) / BMS, Ono Pharma, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, PD(L)-1 Biomarker, Metastases: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data. (Pubmed Central) - Aug 13, 2024
Nivolumab plus relatlimab demonstrated similar efficacy to nivolumab plus ipilimumab in the overall population, including most-but not all-subgroups, and improved safety in patients with untreated advanced melanoma. Results should be interpreted with caution.
- | Journal: Current treatments for oropharyngeal squamous cell carcinoma and the move towards molecular therapy. (Pubmed Central) - Aug 13, 2024
Results should be interpreted with caution. Molecular therapy is largely at the preclinical stage, with cetuximab, nivolumab, pembrolizumab, Lenvatinib, and bevacizumab being tested clinically currently.
- | Rituxan (rituximab) / Roche
Journal: Ten years of detecting Neoehrlichia mikurensis infections in Sweden: demographic, clinical and inflammatory parameters. (Pubmed Central) - Aug 13, 2024
Molecular therapy is largely at the preclinical stage, with cetuximab, nivolumab, pembrolizumab, Lenvatinib, and bevacizumab being tested clinically currently. Neoehrlichiosis is a multi-faceted emerging infectious disease.
- || Rituxan (rituximab) / Roche
Clinical, Retrospective data, Journal: Rituximab therapy for adult refractory systemic lupus erythematosus with neurological and/or psychiatric presentations: a PRISMA-compliant meta-analysis. (Pubmed Central) - Aug 13, 2024
RTX therapy had good effectiveness. The pooled evidence for safety outcomes was limited and of low certainty.
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Journal: CDK4/6 Inhibitors Impede Chemoresistance and Inhibit Tumor Growth of Small Cell Lung Cancer. (Pubmed Central) - Aug 13, 2024
The pooled evidence for safety outcomes was limited and of low certainty. In this study, it is
- || Kisqali (ribociclib) / Novartis
Clinical, P2 data, Journal, Metastases: Initial ribociclib plus endocrine therapy for HR+/HER2- advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study. (Pubmed Central) - Aug 13, 2024
In this study, it is No abstract available
- | Gazyva (obinutuzumab) / Roche, Biogen, Rituxan (rituximab) / Roche
Journal: Case report: Effective treatment of rituximab-resistant minimal change disease with obinutuzumab in an adult. (Pubmed Central) - Aug 13, 2024
This case demonstrates the successful treatment of frequently relapsed, steroid-dependent, and rituximab-resistant MCD with obinutuzumab. Obinutuzumab is a promising therapeutic option for rituximab-resistant MCD.
- | Opdivo (nivolumab) / BMS
Biomarker, Retrospective data, Journal, PD(L)-1 Biomarker, IO biomarker: Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma. (Pubmed Central) - Aug 13, 2024
Obinutuzumab is a promising therapeutic option for rituximab-resistant MCD. The frequency of natural killer cells was associated with nivolumab response in patients with prior cetuximab use, but not in cetuximab-na
- | Loqtorzi (toripalimab-tpzi) / Shanghai Junshi Biosci, Coherus Biosci
Journal, HEOR, Cost-effectiveness, Cost effectiveness, Metastases: Toripalimab plus chemotherapy in the treatment of metastatic triple-negative breast cancer: a cost-effectiveness analysis. (Pubmed Central) - Aug 13, 2024
This study suggests that the addition of toripalimab to chemotherapy for the treatment of mTNBC is a cost-effective strategy. The findings provide valuable evidence to guide decision-making regarding treatment selection for patients with mTNBC in China.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Journal: Cutaneous Anaplastic T-Cell Lymphoma Mimicking a Small Abscess: A Case Report. (Pubmed Central) - Aug 13, 2024
While the initial presentation mimicked an infectious process, the biopsy revealed a possible cutaneous anaplastic T-cell lymphoma. Further investigations are necessary to definitively classify the specific lymphoma subtype and guide further treatment decisions.
- | Nucala (mepolizumab) / GSK, Rituxan (rituximab) / Roche
Journal: The Puzzling Coexistence of Eosinophilic Pneumonia With Sjogren's Syndrome: A Diagnostic Dilemma. (Pubmed Central) - Aug 13, 2024
We present a case where a patient with no significant pulmonary nor autoimmune medical history presents with acute hypoxic respiratory failure and a dry cough that's made worse when conversing. She gets diagnosed with eosinophilic pneumonia after bronchoalveolar lavage (BAL) showed 70% eosinophils while also having labs highly suggestive of primary Sjogren's syndrome (pSS) with an anti-SSA titer of 111.3 U/mL and anti-SSA 52 kD Ab, immunoglobulin (Ig)G >200 U. The initial treatment plan was to start rituximab to target
- ||| Tecentriq (atezolizumab) / Roche
Journal, Adverse events, PD(L)-1 Biomarker, IO biomarker: Immune-related adverse event-myocarditis with marked ST-segment elevation requiring differentiation from COVID-19-induced myocarditis: a case report. (Pubmed Central) - Aug 13, 2024
A 64-year-old man with a history of seven courses of atezolizumab, an ICI, for small-cell lung cancer and coronavirus disease 2019 (COVID-19) was admitted to the hospital complaining of acute chest pain...The histopathological findings suggested the high possibility of irAE-myocarditis rather than COVID-19-induced myocarditis, but COVID-19 has possibly played a role in the development of late-onset irAE-myocarditis. This educational case implies the importance of immediate recognition of irAE even after stable ICI treatment.
- || Nplate (romiplostim) / Amgen, Kyowa Kirin
Review, Journal: Romiplostim in chemotherapy-induced thrombocytopenia: A review of the literature. (Pubmed Central) - Aug 13, 2024
Recent treatment guidelines, including those from the National Comprehensive Cancer Network, now support consideration of romiplostim use in CIT. Data are expected from two ongoing phase 3 romiplostim CIT trials.
- || Rituxan (rituximab) / Roche
Review, Journal: Update on systemic sclerosis (Pubmed Central) - Aug 13, 2024
The diagnosis and treatment of systemic sclerosis is making progress and many symptoms and complications are treatable. Nevertheless, much remains to be done to improve the quality of life of the patients.
- | Rituxan (rituximab) / Roche
Journal: Low risk of hepatitis B virus reactivation in membranous nephropathy patients with resolved infection undergoing rituximab-based regimens without antiviral prophylaxis. (Pubmed Central) - Aug 13, 2024
The administration of rituximab-based regimens in membranous nephropathy patients with hepatitis B virus resolved infection leads to a low risk of hepatitis B virus reactivation without antiviral prophylaxis. Patient's immune status, drug combination, rituximab strategy should be fully evaluated when considering antiviral prophylaxis therapy.
- | Avastin (bevacizumab) / Roche, Tecentriq (atezolizumab) / Roche
Journal: Atezolizumab and bevacizumab plus transarterial chemoembolization and hepatic arterial infusion chemotherapy for patients with high tumor burden unresectable hepatocellular carcinoma: A multi-center cohort study. (Pubmed Central) - Aug 13, 2024
Patient's immune status, drug combination, rituximab strategy should be fully evaluated when considering antiviral prophylaxis therapy. The findings underscore the potential of the A+B and TACE-HAIC combined treatment for HTB-uHCC patients, marking it as a viable therapeutic option, given its potent efficacy and tolerable safety profile.
- | Rituxan (rituximab) / Roche
Journal, IO biomarker: Development of a targeted IL-12 immunotherapy platform for B-cell lymphomas. (Pubmed Central) - Aug 13, 2024
Our results revealed that CD20-IL-12mut exhibited potent anticancer activity by inducing complete regression and generating immunological memory for tumor antigens. Collectively, our data provide a basis for additional research on CD20-IL-12mut as a potential treatment choice for patients with B-cell lymphomas such as non-Hodgkin's lymphoma.
- | Rituxan (rituximab) / Roche
Journal: Evaluation of pediatric rheumatologists' approach to rituximab use: a questionnaire study. (Pubmed Central) - Aug 13, 2024
RTX has become a common treatment option in pediatric rheumatology in recent years. Treatment management may vary between clinician such as vaccination and routine tests.
- | Keytruda (pembrolizumab) / Merck (MSD), Avastin (bevacizumab) / Roche
New P4 trial, Combination therapy, IO biomarker, Metastases: Safety and Efficacy of Pembrolizumab in Combination With Bevacizumab + CapeOX in the Neoadjuvant Treatment of RAS-mutated, BRAF Wild-type, Microsatellite-stabilized, Locally Advanced Colorectal Cancer (clinicaltrials.gov) - Aug 13, 2024
P4, N=20, Recruiting, Sponsor: yangjianjun
- || dalutrafusp alfa (AGEN1423) / Agenus, botensilimab (AGEN1181) / Agenus
Enrollment open, Combination therapy, Metastases: AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC (clinicaltrials.gov) - Aug 13, 2024
P2, N=24, Recruiting, Sponsor: Bruno Bockorny
Treatment management may vary between clinician such as vaccination and routine tests. Not yet recruiting --> Recruiting
- ||| Tevimbra (tislelizumab-jsgr) / BeiGene
Trial completion, Combination therapy: BGB-A317-212: To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Patients With Selected Solid Tumors (clinicaltrials.gov) - Aug 13, 2024
P2, N=58, Completed, Sponsor: BeiGene
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- || Tevimbra (tislelizumab-jsgr) / BeiGene, BGB-A445 / BeiGene
Enrollment change, Combination therapy, Metastases: BGB-A317-A445-101: Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Aug 13, 2024
P1, N=342, Active, not recruiting, Sponsor: BeiGene
Active, not recruiting --> Completed N=203 --> 342
- | Fruzaqla (fruquintinib) / Takeda, Kaitanni (cadonilimab) / Akesobio
New trial, Metastases: Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC (clinicaltrials.gov) - Aug 13, 2024
P=N/A, N=80, Recruiting, Sponsor: Liu Huang
- | Tyvyt (sintilimab) / Eli Lilly
Trial completion, Trial completion date, Trial primary completion date: INOVA: Sintilimab Plus Bevacizumab in Recurrent/Persistent Ovarian Clear Cell Carcinoma (clinicaltrials.gov) - Aug 13, 2024
P2, N=38, Completed, Sponsor: Tongji Hospital
N=203 --> 342 Recruiting --> Completed | Trial completion date: Apr 2024 --> Jul 2024 | Trial primary completion date: Apr 2024 --> Jul 2024
- | Xpovio (selinexor) / Karyopharm
Enrollment closed: Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma (clinicaltrials.gov) - Aug 13, 2024
P2, N=18, Active, not recruiting, Sponsor: University of Colorado, Denver
Recruiting --> Completed | Trial completion date: Apr 2024 --> Jul 2024 | Trial primary completion date: Apr 2024 --> Jul 2024 Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Trial primary completion date: NeoRad: BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab (clinicaltrials.gov) - Aug 13, 2024
P2, N=25, Recruiting, Sponsor: Brown University
Recruiting --> Active, not recruiting Trial primary completion date: Apr 2024 --> Oct 2024
- || Carvykti (ciltacabtagene autoleucel) / J&J, Talvey (talquetamab-tgvs) / J&J
New P2 trial: MonumenTAL-8: A Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma (clinicaltrials.gov) - Aug 13, 2024
P2, N=30, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- ||| ianalumab (VAY736) / Novartis
Trial completion date: NEPTUNUS-2: Three-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (clinicaltrials.gov) - Aug 13, 2024
P3, N=505, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Trial primary completion date: Apr 2024 --> Oct 2024 Trial completion date: Mar 2028 --> May 2027
- ||| Fabhalta (iptacopan) / Novartis
Enrollment open: Iptacopan in Patients With ANCA Associated Vasculitis (clinicaltrials.gov) - Aug 12, 2024
P2, N=78, Recruiting, Sponsor: Novartis Pharmaceuticals
Trial completion date: Mar 2028 --> May 2027 Not yet recruiting --> Recruiting
- | Opdivo (nivolumab) / BMS
Trial completion, Trial completion date, Trial primary completion date, Metastases: ImmunoSarc: Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas (clinicaltrials.gov) - Aug 12, 2024
P1/2, N=197, Completed, Sponsor: Grupo Espanol de Investigacion en Sarcomas
Not yet recruiting --> Recruiting Recruiting --> Completed | Trial completion date: Jun 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024
- | Opdivo (nivolumab) / BMS
Trial completion date, Trial primary completion date: ANICCA: A Phase II Trial Assessing Nivolumab in Class II Expressing Microsatellite Stable Colorectal Cancer (clinicaltrials.gov) - Aug 12, 2024
P2, N=35, Active, not recruiting, Sponsor: University of Birmingham
Recruiting --> Completed | Trial completion date: Jun 2025 --> Jun 2024 | Trial primary completion date: Jun 2025 --> Jun 2024 Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024
- ||| VTP-300 / Vaccitech
Trial completion, Phase classification: First-In-Human Study of ChAdOx1-HBV & MVA-HBV Vaccines (VTP-300) for Chronic HBV (clinicaltrials.gov) - Aug 12, 2024
P1/2, N=55, Completed, Sponsor: Barinthus Biotherapeutics
Trial completion date: Jul 2024 --> Oct 2024 | Trial primary completion date: Jul 2024 --> Oct 2024 Active, not recruiting --> Completed | Phase classification: P1b/2a --> P1/2
- |||| ianalumab (VAY736) / Novartis
Trial completion date, Trial primary completion date: NEPTUNUS-1: Two-arm Study to Assess Efficacy and Safety of Ianalumab (VAY736) in Patients With Active Sjogren's Syndrome (clinicaltrials.gov) - Aug 12, 2024
P3, N=276, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Active, not recruiting --> Completed | Phase classification: P1b/2a --> P1/2 Trial completion date: Mar 2028 --> Mar 2027 | Trial primary completion date: Mar 2026 --> May 2025
- | Mylotarg (gemtuzumab ozogamicin) / UCB, PDL, Pfizer
Journal: Can we do better with Mylotarg? Model-based assessment of opportunities to improve therapeutic index. (Pubmed Central) - Aug 12, 2024
Alternatively, a longer-circulating Mylotarg formulation could obviate the need for dose fractionation, allowing superior patient convenience. Early-stage PK optimization through quantitative modeling methods can accelerate clinical development and prevent late-stage failures.
- | SCRI-CAR19 / Seattle Children's Hospital
Journal, CAR T-Cell Therapy: Feasibility and Favorable Responses Following Investigational CAR T-Cell Therapy for Relapsed and Refractory Infant ALL. (Pubmed Central) - Aug 12, 2024
Grade 2. With the successful early clinical experience of CAR T-cell therapy in this population, more systematic evaluation specific to infant ALL is warranted.
- | Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis, Yervoy (ipilimumab) / BMS
Journal, Metastases: Cabozantinib plus ipilimumab/nivolumab in patients with previously treated advanced differentiated thyroid cancer. (Pubmed Central) - Aug 12, 2024
P2
With the successful early clinical experience of CAR T-cell therapy in this population, more systematic evaluation specific to infant ALL is warranted. CaboNivoIpi had low ORRs and a high rate of grade ?3 treatment-related AEs.
- || Orencia (abatacept) / BMS
Clinical, Retrospective data, Journal, Real-world evidence, Real-world: Abatacept versus tumor necrosis factor inhibitors on mortality and medical utilizations in the treatment of rheumatoid arthritis associated interstitial lung disease: a large-scale real-world retrospective cohort study. (Pubmed Central) - Aug 12, 2024
CaboNivoIpi had low ORRs and a high rate of grade ?3 treatment-related AEs. This real-world data research demonstrated a higher risk of all-cause mortality in RA-ILD patients treated with ABA compared to TNFi, particularly those aged 18-64
- | Ibrance (palbociclib) / Pfizer, Kisqali (ribociclib) / Novartis
Retrospective data, Journal, Real-world evidence, Real-world, Metastases: Real-world experience with CDK4/6 inhibitors in hormone receptor-positive metastatic and recurrent breast cancer: findings from an Asian population. (Pubmed Central) - Aug 12, 2024
Treatment outcomes between the two types of CDK4/6i did not differ significantly, indicating the safety and efficacy of CDK4/6i for the Asian population. Ribociclib and palbociclib showed similar efficacy in PFS in the real-world setting.
- | UV1 / Ultimovacs, Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
Journal, FDG PET: Outcome prediction based on [18F]FDG PET/CT in patients with pleural mesothelioma treated with ipilimumab and nivolumab +/- UV1 telomerase vaccine. (Pubmed Central) - Aug 12, 2024
P2
High SUVpeak was not associated with inferior outcomes, which could be attributed to the distinct mechanisms of immunotherapy. Early reductions in PET metrics correlated with treatment response.
- | Adcetris (brentuximab vedotin) / Takeda, Pfizer
Journal, Metastases: Efficacy of escalating therapy with brentuximab vedotin-AVD in advanced stage Hodgkin lymphoma patients with positive interim positron emission tomography after ABVD. (Pubmed Central) - Aug 12, 2024
At a median 17-month follow-up, all patients are alive, 87% in complete remission, and 1-year PFS was 57.8%. For patients ineligible for BEACOPP due to age, comorbidities, or preference, A-AVD escalation may be a viable alternative.